Next Article in Journal
Arterial Function in Healthy Pregnant Women vs. Non-Pregnant Women—A 10-Year Study
Previous Article in Journal
Evaluation of ViroTrack Sero Zika IgG/IgM, a New Rapid and Quantitative Zika Serological Diagnostic Assay
Open AccessArticle

Lymph Node Number Predicts the Efficacy of Adjuvant Chemoradiotherapy in Node-Positive Endometrial Cancer Patients

by Jie Lee 1,2, Tsung Yu 3 and Mu-Hung Tsai 4,5,*
1
Department of Radiation Oncology, MacKay Memorial Hospital, Taipei 104, Taiwan
2
Department of Medicine, MacKay Medical College, New Taipei City 252, Taiwan
3
Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
4
Department of Radiation Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan
5
Department of Computer Science and Information Engineering, College of Electrical Engineering and Computer Science, National Cheng Kung University, Tainan 701, Taiwan
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(6), 373; https://doi.org/10.3390/diagnostics10060373
Received: 12 May 2020 / Revised: 28 May 2020 / Accepted: 3 June 2020 / Published: 4 June 2020
(This article belongs to the Section Pathology and Molecular Diagnostics)
This study aimed to evaluate the value of lymph node (LN) number as a predictor for adjuvant treatment in node-positive endometrial cancer. Data of 441 patients diagnosed with International Federation of Gynaecology and Obstetrics (FIGO) stage IIIC endometrial cancer and who underwent adjuvant chemotherapy alone or chemoradiotherapy between 2009 and 2015 from the Taiwan Cancer Registry were reviewed. The patients were stratified based on the number of positive LN as follows: 1, 2–5, and ≥ 6. The overall survival (OS) was analysed using the Kaplan–Meier method and the Cox proportional hazards model. In multivariable analysis, chemoradiotherapy was independently associated with improved OS (hazard ratio [HR]: 0.62, 95% confidence interval [CI]: 0.43–0.90; p = 0.01) compared with chemotherapy alone. Patients with ≥ 6 positive LNs were associated with a worse OS (HR: 2.22, 95% CI: 1.25–3.95; p = 0.006) and those with 2–5 LNs were not associated with a worse OS (HR: 1.56, 95% CI: 0.94–2.59; p = 0.09) compared to patients with one LN. When stratified based on LN number, chemoradiotherapy was found to significantly improve the 5-year OS of patients with ≥ 6 positive LNs compared to chemotherapy alone (35.9% vs. 70.0%, p < 0.001). No significant differences between chemotherapy alone and chemoradiotherapy were observed in 5-year OS among patients with one LN (73.1% vs. 80.8%, p = 0.31) or 2–5 positive LNs (71.4% vs. 75.7%, p = 0.68). Lymph node number may be used to identify node-positive endometrial cancer patients who are likely to have improved OS with intensification of adjuvant therapy. View Full-Text
Keywords: endometrial cancer; radiotherapy; chemotherapy; lymph node endometrial cancer; radiotherapy; chemotherapy; lymph node
Show Figures

Figure 1

MDPI and ACS Style

Lee, J.; Yu, T.; Tsai, M.-H. Lymph Node Number Predicts the Efficacy of Adjuvant Chemoradiotherapy in Node-Positive Endometrial Cancer Patients. Diagnostics 2020, 10, 373.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop